Open an account

Zura Bio

ZURA · NASDAQ

$4.00+$0.19 (+4.99%)TodayMarket closed ·
Prev close $3.81

About ZURA

Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 40 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Employees
40
Headquarters
La Jolla, California
Listed
Jul 16, 2021
Sector
Health Care
Industry
Biotechnology
Website
zurabio.com

ZURA key statistics

Market cap
526.29M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.92M
Volume
3.32M
Open price
$3.83
High today
$4.21
Low today
$3.81
52 Week high
$7.44
52 Week low
$3.15

Zura Bio (ZURA) at a glance

As of Oct 20, 2026, Zura Bio (ZURA) shares are priced at $4.00, giving the company a market cap of 526.29M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.81 and $4.21. The current price is 5.0% above the day's low and 5.0% below its high.

Volume so far is 3.32M shares, in line with the average of 3.92M shares a day.

Over the past year Zura Bio has ranged from $3.15 to $7.44, and now sits 20% of the way up that range.

Zura Bio met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.21 per share against an estimate of -$0.2011.

The average analyst price target is $19.21, 380.2% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $19.21
Low
$11.11
Now
$4.00
High
$27.30

ZURA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 24.2% on average.

  1. Q3 FY24: reported -$0.26 per share against an estimate of -$0.1258
  2. Q4 FY24: reported -$0.10 per share against an estimate of -$0.1583
  3. Q1 FY25: reported -$0.19 per share against an estimate of -$0.1617
  4. Q2 FY25: reported -$0.17 per share against an estimate of -$0.1921
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.1851
  6. Q4 FY25: reported -$0.49 per share against an estimate of -$0.2004
  7. Q1 FY26: reported -$0.22 per share against an estimate of -$0.1775
  8. Q2 FY26: reported -$0.21 per share against an estimate of -$0.2011

ZURA news

  • Press releaseBusiness Wire

    Zura Bio to Participate in the Cantor Global Healthcare Conference

  • Press releaseBusiness Wire

    Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

  • Vandana Singh

    Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy

  • Press releaseBusiness Wire

    Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

  • Press releaseBusiness Wire

    Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

  • Press releaseBusiness Wire

    Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Similar companies

Companies in the same industry as Zura Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.